Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186114733> ?p ?o ?g. }
- W3186114733 endingPage "103380" @default.
- W3186114733 startingPage "103380" @default.
- W3186114733 abstract "Several pilot studies have provided evidence supporting the potential of classic psychedelics like psilocybin in the treatment of substance use disorders (SUDs). If larger trials confirm efficacy, classic psychedelic-assisted psychotherapy may eventually be integrated into existing addiction treatments such as cognitive behavioral therapy, contingency management, and medication-assisted therapies. Many individuals seeking treatment for SUDs also join twelve-step facilitation (TSF) programs like Alcoholics Anonymous (AA), which are among the most widely available and accessed treatments for alcohol use disorder worldwide. For such individuals, engaging in classic psychedelic-assisted psychotherapy could be seen as controversial, as members of AA/TSF programs have historically rejected medication-assisted treatments in favor of a pharmacotherapy-free approach. We argue that classic psychedelics and the subjective experiences they elicit may represent a special, more compatible case than conventional medications. In support of this claim, we describe Bill Wilson's (the founder of AA) little known experiences with psychedelics and on this basis, we argue that aspects of classic psychedelic treatments could complement AA/TSF programs. We provide a review of clinical trials evaluating psychedelics in the context of SUDs and discuss their potential large-scale impact should they be ultimately integrated into AA/TSF." @default.
- W3186114733 created "2021-08-02" @default.
- W3186114733 creator A5004506349 @default.
- W3186114733 creator A5030387003 @default.
- W3186114733 creator A5034301856 @default.
- W3186114733 creator A5039486115 @default.
- W3186114733 creator A5070783585 @default.
- W3186114733 creator A5091708678 @default.
- W3186114733 date "2021-12-01" @default.
- W3186114733 modified "2023-10-02" @default.
- W3186114733 title "Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs" @default.
- W3186114733 cites W1957998952 @default.
- W3186114733 cites W1961210484 @default.
- W3186114733 cites W1973613743 @default.
- W3186114733 cites W1973814761 @default.
- W3186114733 cites W1974524186 @default.
- W3186114733 cites W1983911930 @default.
- W3186114733 cites W1984709753 @default.
- W3186114733 cites W2001101493 @default.
- W3186114733 cites W2006587749 @default.
- W3186114733 cites W2013762461 @default.
- W3186114733 cites W2016744112 @default.
- W3186114733 cites W2025716661 @default.
- W3186114733 cites W2038786381 @default.
- W3186114733 cites W2070626685 @default.
- W3186114733 cites W2075238613 @default.
- W3186114733 cites W2078821747 @default.
- W3186114733 cites W2088785539 @default.
- W3186114733 cites W2089857026 @default.
- W3186114733 cites W2091746900 @default.
- W3186114733 cites W2094933578 @default.
- W3186114733 cites W2096164110 @default.
- W3186114733 cites W2096567449 @default.
- W3186114733 cites W2096571901 @default.
- W3186114733 cites W2111920357 @default.
- W3186114733 cites W2112884745 @default.
- W3186114733 cites W2113099805 @default.
- W3186114733 cites W2114302411 @default.
- W3186114733 cites W2116852450 @default.
- W3186114733 cites W2117864279 @default.
- W3186114733 cites W2119738402 @default.
- W3186114733 cites W2121441663 @default.
- W3186114733 cites W2122459973 @default.
- W3186114733 cites W2132978162 @default.
- W3186114733 cites W2135421583 @default.
- W3186114733 cites W2137983723 @default.
- W3186114733 cites W2140013897 @default.
- W3186114733 cites W2160313238 @default.
- W3186114733 cites W2161555895 @default.
- W3186114733 cites W2243916050 @default.
- W3186114733 cites W2318552418 @default.
- W3186114733 cites W2340085151 @default.
- W3186114733 cites W2396675581 @default.
- W3186114733 cites W2408251447 @default.
- W3186114733 cites W2419844652 @default.
- W3186114733 cites W2513336695 @default.
- W3186114733 cites W2537027964 @default.
- W3186114733 cites W2558412547 @default.
- W3186114733 cites W2559739670 @default.
- W3186114733 cites W2573408014 @default.
- W3186114733 cites W2588071311 @default.
- W3186114733 cites W2610309226 @default.
- W3186114733 cites W2762822955 @default.
- W3186114733 cites W2767530231 @default.
- W3186114733 cites W2777220936 @default.
- W3186114733 cites W2806419184 @default.
- W3186114733 cites W2883252198 @default.
- W3186114733 cites W2894541203 @default.
- W3186114733 cites W2903001666 @default.
- W3186114733 cites W2914888340 @default.
- W3186114733 cites W2940999002 @default.
- W3186114733 cites W2942662903 @default.
- W3186114733 cites W2944337860 @default.
- W3186114733 cites W2945506353 @default.
- W3186114733 cites W2952169207 @default.
- W3186114733 cites W2953078658 @default.
- W3186114733 cites W2971319118 @default.
- W3186114733 cites W2994787463 @default.
- W3186114733 cites W3001327571 @default.
- W3186114733 cites W3004690109 @default.
- W3186114733 cites W3118498264 @default.
- W3186114733 cites W3137839889 @default.
- W3186114733 cites W3156937150 @default.
- W3186114733 cites W4211211437 @default.
- W3186114733 doi "https://doi.org/10.1016/j.drugpo.2021.103380" @default.
- W3186114733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34329952" @default.
- W3186114733 hasPublicationYear "2021" @default.
- W3186114733 type Work @default.
- W3186114733 sameAs 3186114733 @default.
- W3186114733 citedByCount "16" @default.
- W3186114733 countsByYear W31861147332021 @default.
- W3186114733 countsByYear W31861147332022 @default.
- W3186114733 countsByYear W31861147332023 @default.
- W3186114733 crossrefType "journal-article" @default.
- W3186114733 hasAuthorship W3186114733A5004506349 @default.
- W3186114733 hasAuthorship W3186114733A5030387003 @default.
- W3186114733 hasAuthorship W3186114733A5034301856 @default.
- W3186114733 hasAuthorship W3186114733A5039486115 @default.